Journal of Pharmaceutical Sciences
type: Collection
type: Document
type: Generically Dependent Continuant
type: Entity
type: Thing
type: Periodical
publication venue for: Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy
type: Information Content Entity
type: Journal
type: Continuant

Document
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy - http://orbis.uaslp.mx/vivo/individual/scopus6430
rights: termsOfUse
date: 2026-08-24T21:51:02
publisher: vivo
type: Document

Article
type: Class

APP1099452, APP1117065
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy

Information Content Entity
type: Class

Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy
related by: authorship_41824
type: Document
most specific type: Document
volume: 109
type: Generically Dependent Continuant
abstract: The objective was to develop and externally validate a population pharmacokinetic model of levetiracetam in adult and elderly patients with epilepsy, and to perform dosing simulations to propose individualized dosing regimens more likely to achieve therapeutic concentrations. This prospective study included 367 plasma samples from 107 patients receiving oral levetiracetam. Samples were analyzed by HPLC-UV. Pharmacokinetic data, as well as patient demographic, clinical characteristics, other drug therapy, and the use of innovator or generic products of levetiracetam, were collected. Population modeling was performed with NONMEM and included internal and external validations of the final model. Simulations were used to propose optimized dosing regimens. The pharmacokinetics of levetiracetam was described by a one-compartment model with first-order absorption and linear elimination. Body surface area had a significant effect on the apparent volume of distribution, as did creatinine clearance (CrCL) over the drug clearance (p < 0.01). The final model performed adequately during external validation testing. The final model showed a better predictive performance. Dosing simulations support 1000 mg 12-hourly dosing of levetiracetam for patients with CrCL ~60-75 mL/min with higher dose needed for higher values (1500 mg 12-hourly for CrCL ~93-111 mL/min). Dosing regimens should be personalized to the patient%27s CrCL to maximize the likelihood of therapeutic concentrations. © 2020 American Pharmacists Association®
chemicalscas: creatinine, 19230-81-0, 60-27-5; levetiracetam, 102767-28-2
most specific type: Article
issue: 6
page end: 2078
type: Thing
related by: authorship_41830
related by: authorship_41828
estado: published
related by: authorship_41826
abstract: The objective was to develop and externally validate a population pharmacokinetic model of levetiracetam in adult and elderly patients with epilepsy, and to perform dosing simulations to propose individualized dosing regimens more likely to achieve therapeutic concentrations. This prospective study included 367 plasma samples from 107 patients receiving oral levetiracetam. Samples were analyzed by HPLC-UV. Pharmacokinetic data, as well as patient demographic, clinical characteristics, other drug therapy, and the use of innovator or generic products of levetiracetam, were collected. Population modeling was performed with NONMEM and included internal and external validations of the final model. Simulations were used to propose optimized dosing regimens. The pharmacokinetics of levetiracetam was described by a one-compartment model with first-order absorption and linear elimination. Body surface area had a significant effect on the apparent volume of distribution, as did creatinine clearance (CrCL) over the drug clearance (p < 0.01). The final model performed adequately during external validation testing. The final model showed a better predictive performance. Dosing simulations support 1000 mg 12-hourly dosing of levetiracetam for patients with CrCL ~60-75 mL/min with higher dose needed for higher values (1500 mg 12-hourly for CrCL ~93-111 mL/min). Dosing regimens should be personalized to the patient's CrCL to maximize the likelihood of therapeutic concentrations. © 2020 American Pharmacists Association®
freetext keyword: dosing; epilepsy; levetiracetam; population pharmacokinetics; renal function; therapeutic drug monitoring creatinine; levetiracetam; adult; age; aged; Article; body surface; compartment model; controlled study; creatinine clearance; drug absorption; drug clearance; drug elimination; epilepsy; female; human; major clinical study; male; population research; prediction; prospective study; simulation; ultra performance liquid chromatography; ultraviolet radiation; validation study; volume of distribution
related by: authorship_41823
has funding vehicle: APP1099452, APP1117065
type: Information Content Entity
page start: 2070
e iscopus: 2-s2.0-85082533723
crisid: 6431
related by: authorship_41825
related by: authorship_41827
date time value: article date 6431
related by: authorship_41822
type: Entity
has funding vehicle: Consejo Nacional de Ciencia y Tecnología, CONACYT: 438079
has publication venue: Journal of Pharmaceutical Sciences
pmid: 32113977
doi: 10.1016/j.xphs.2020.02.018
type: Continuant
type: Article
has funding vehicle: Consejo Nacional de Ciencia y Tecnología, Paraguay, El CONACYT: C-891/2018
origen: scopus
related by: authorship_41829

Consejo Nacional de Ciencia y Tecnología, Paraguay, El CONACYT: C-891/2018
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
label: Consejo Nacional de Ciencia y Tecnologí­a, Paraguay, El CONACYT: C-891/2018
funding vehicle for: Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy

Consejo Nacional de Ciencia y Tecnología, CONACYT: 438079
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy